Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients

References

• Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer-Am Cancer Soc. 2007;110(10):2339–2346. doi: 10.1002/cncr.23062
   Google Scholar
• Smith JA. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Urol. 2005;174(4 Pt 1):1300. doi: 10.1097/01.ju.0000178536.63739.af
   PubMedGoogle Scholar
• Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–1969. doi: 10.1182/blood.2020007338
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. New Engl J Med. 2000;343(25):1846–1850. doi: 10.1056/NEJM200012213432504
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang G, Zhang M, et al. Development and validation of a risk score for prediction of venous thromboembolism in patients with lung cancer. Clin Appl Thromb Hem. 2020;26:1076029620910793. doi: 10.1177/1076029620910793
   Web of Science ®Google Scholar
• Howlett J, Benzenine E, Cottenet J, et al. Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study. BMC Cancer. 2020;20(1):461. doi: 10.1186/s12885-020-06930-1
   PubMed Web of Science ®Google Scholar
• Roopkumar J, Poudel SK, Gervaso L, et al. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: a cohort study. J Thromb Haemost. 2021;19(3):822–829. doi: 10.1111/jth.15215
   PubMed Web of Science ®Google Scholar
• Davidsson E, Murgia N, Ortiz-Villalón C, et al. Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma. Multidiscip Resp Med. 2017;12(1):16. doi: 10.1186/s40248-017-0097-0
   PubMedGoogle Scholar
• Horsted F, West J, Grainge MJ, et al. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLOS Med. 2012;9(7):e1001275. doi: 10.1371/journal.pmed.1001275
   PubMed Web of Science ®Google Scholar
• Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718–1729. doi: 10.1016/S0140-6736(22)00562-1
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Engl J Med. 2016;375(19):1823–1833. doi: 10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021;22(7):946–958. doi: 10.1016/S1470-2045(21)00241-2
   PubMed Web of Science ®Google Scholar
• Johnson J, Bar Ad V, Lorber E, et al. Nivolumab (nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). J Clin Oncol. 2020;38(15_suppl):6577–6577. doi: 10.1200/JCO.2020.38.15_suppl.6577
   Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi: 10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA-Cancer J Clin. 2020;70(2):86–104. doi: 10.3322/caac.21596
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–266. doi: 10.6004/jnccn.2021.0013
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907. doi: 10.1182/blood-2007-10-116327
   PubMed Web of Science ®Google Scholar
• Ke L, Cui S, Chen S, et al. Dynamics of D-dimer in non-small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism. Thorac Cancer. 2020;11(9):2483–2492. doi: 10.1111/1759-7714.13559
   PubMed Web of Science ®Google Scholar
• Rupa-Matysek J, Lembicz M, Rogowska EK, et al. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018;35(5):63. doi: 10.1007/s12032-018-1120-9
   PubMed Web of Science ®Google Scholar
• Guo J, Deng QF, Xiong W, et al. Comparison among different presentations of venous thromboembolism because of lung cancer. Clin Respir J. 2019;13(9):574–582. doi: 10.1111/crj.13060
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Y, Chen W, et al. Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer. Sci Rep. 2016;6:19603. doi: 10.1038/srep19603
   PubMed Web of Science ®Google Scholar
• Kadlec B, Skrickova J, Merta Z, et al. The incidence and predictors of thromboembolic events in patients with lung cancer. Sci World J. 2014;2014:125706. doi: 10.1155/2014/125706
   Web of Science ®Google Scholar
• Malgor RD, Bilfinger TV, Labropoulos N. A systematic review of pulmonary embolism in patients with lung cancer. Ann Thorac Surg. 2012;94(1):311–316. doi: 10.1016/j.athoracsur.2012.03.025
   PubMed Web of Science ®Google Scholar
• Zheng LX, Li L, Huang JH, et al. Venous thromboembolism in patients with severe lung cancer: a narrative review. Ann Palliat Med. 2021;10(6):6957–6967. doi: 10.21037/apm-21-1281
   PubMed Web of Science ®Google Scholar
• Jin YF, Ye YQ, Jin YJ, et al. Risk factors and impact on outcomes of lung cancer patients concurrent with Deep Vein Thrombosis. Cancer Control. 2022;29:10732748221145074. doi: 10.1177/10732748221145074
   Web of Science ®Google Scholar
• Castellón Rubio VE, Segura PP, Muñoz A, et al. High plasma levels of soluble P-Selectin and factor VIII predict venous thromboembolism in non-small cell lung cancer patients: the thrombo-nsclc risk score. Thromb Res. 2020;196:196 349–354. doi: 10.1016/j.thromres.2020.09.021
   PubMed Web of Science ®Google Scholar
• Tsubata Y, Kawakado K, Hamai K, et al. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective rising-VTE/NEJ037 study data. Int J Clin Oncol. 2022;28(1):69–78. doi: 10.1007/s10147-022-02257-y
   PubMed Web of Science ®Google Scholar
• Akasaka-Kihara F, Sueta D, Ishii M, et al. Validation of the Khorana venous thromboembolism risk score in Japanese cancer patients. 2021;1(2):259–270. doi: 10.1016/j.jacasi.2021.07.006
   Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. New Engl J Med. 2019;380(8):720–728. doi: 10.1056/NEJMoa1814630
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. New Engl J Med. 2018;380(8):711–719. doi: 10.1056/NEJMoa1814468
   PubMed Web of Science ®Google Scholar
• Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(10):1181–1201.
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2019;38(5):496–520. doi: 10.1200/JCO.19.01461
   PubMed Web of Science ®Google Scholar
• Ruiz-Artacho P, Trujillo-Santos J, López-Jiménez L, et al. Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism. TH Open. 2018;2(2):e210–e217. doi: 10.1055/s-0038-1656542
   PubMedGoogle Scholar
• Walker AJ, Baldwin DR, Card TR, et al. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. Br J Cancer. 2016;115(1):115–121. doi: 10.1038/bjc.2016.143
   PubMed Web of Science ®Google Scholar
• Wang Z, Yan HH, Yang JJ, et al. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer. 2014;23(3):635–641. doi: 10.1007/s00520-014-2405-y
   PubMed Web of Science ®Google Scholar
• Kaminuma Y, Tanahashi M, Suzuki E, et al. Venous thromboembolism in non-small cell lung cancer patients who underwent surgery after induction therapy. Gen Thorac Cardiovas. 2020;68(10):1156–1162. doi: 10.1007/s11748-020-01351-0
   PubMed Web of Science ®Google Scholar
• Takemoto T, Soh J, Ohara S, et al. The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. Surg Today. 2021;51(9):1480–1487. doi: 10.1007/s00595-021-02243-3
   PubMed Web of Science ®Google Scholar
• McCrae KR, Swaidani S, Diaz-Montero CM, et al. Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy. Thromb Res. 2022;213(Suppl 1):S51–S57. doi: 10.1016/j.thromres.2022.01.006
   PubMedGoogle Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Icht O, Darzi N, Shimony S, et al. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Haemost. 2021;19(5):1250–1258. doi: 10.1111/jth.15272
   PubMed Web of Science ®Google Scholar
• Alevizakos M, Kaltsas S, Syrigos KN. The VEGF pathway in lung cancer. Cancer Chemoth Pharm. 2013;72(6):1169–1181. doi: 10.1007/s00280-013-2298-3
   PubMed Web of Science ®Google Scholar
• Saerens M, De Jaeghere EA, Kanervo H, et al. Risk of thrombo-embolic events in ovarian cancer: does bevacizumab tilt the scale? a systematic review and meta-analysis. Cancers (Basel). 2021;13(18):4603. doi: 10.3390/cancers13184603
   PubMed Web of Science ®Google Scholar
• Huber ME, Larson E, Lust TN, et al. Chronic obstructive pulmonary disease and cigarette smoke lead to dysregulated mucosal-associated invariant T-cell activation. Am J Resp Cell Mol. 2023;68(1):90–102. doi: 10.1165/rcmb.2022-0131OC
   PubMed Web of Science ®Google Scholar
• Bertoletti L, Couturaud F, Sanchez O, et al. Pulmonary embolism and chronic obstructive pulmonary disease. Semin Thromb Hemost. 2022;49(08):809–815. doi: 10.1055/s-0042-1756190
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos C, Chronis C, Papapetrou E, et al. Prothrombotic state in patients with stable COPD: an observational study. ERJ Open Res. 2021;7(4):00297–2021. doi: 10.1183/23120541.00297-2021
   PubMedGoogle Scholar